PT - JOURNAL ARTICLE AU - Karim, Farina AU - Gazy, Inbal AU - Cele, Sandile AU - Zungu, Yenzekile AU - Krause, Robert AU - Bernstein, Mallory AU - Ganga, Yashica AU - Rodel, Hylton AU - Mthabela, Ntombifuthi AU - Mazibuko, Matilda AU - Khan, Khadija AU - Muema, Daniel AU - Ramjit, Dirhona AU - Lustig, Gila AU - Ndung’u, Thumbi AU - Hanekom, Willem AU - Gosnell, Bernadett I. AU - , AU - Wong, Emily AU - de Oliveira, Tulio AU - Moosa, Mahomed-Yunus S. AU - Leslie, Alasdair AU - Kløverpris, Henrik AU - Sigal, Alex TI - HIV infection alters SARS-CoV-2 responsive immune parameters but not clinical outcomes in COVID-19 disease AID - 10.1101/2020.11.23.20236828 DP - 2020 Jan 01 TA - medRxiv PG - 2020.11.23.20236828 4099 - http://medrxiv.org/content/early/2020/11/24/2020.11.23.20236828.short 4100 - http://medrxiv.org/content/early/2020/11/24/2020.11.23.20236828.full AB - HIV infection alters the immune response and can compromise protective immunity to multiple pathogens following vaccination. We investigated the impact of HIV on the immune response to SARS-CoV-2 using longitudinal samples from 124 participants from KwaZulu-Natal, South Africa, an area of extremely high HIV prevalence. 44% of participants were people living with HIV (PLWH) and commonly had other co-morbidities, including obesity, hypertension, and diabetes. The majority of PLWH but not HIV negative participants showed CD8 T cell expansion above the normal range post-SARS-CoV-2. Yet, in participants with HIV suppressed by antiretroviral therapy (ART), CD8 expansion was associated with milder COVID-19 disease. There were multiple differences in T cell, B cell, and natural killer cell correlations in PLWH compared to HIV negative participants, including lower tissue homing CXCR3+ CD8 T cells in the presence of SARS-CoV-2 RNA in PLWH but not HIV negative and a pronounced early antibody secreting cell (ASC) expansion in HIV negative but not PLWH. These changes were COVID-19 associated: low CXCR3 correlated with increased COVID-19 disease severity across groups, and high ASC correlated with increased disease severity in HIV negative participants and waned when SARS-CoV-2 was cleared. Despite the altered response of immune cell subsets, COVID-19 disease in PLWH was mostly mild and similar to HIV negative participants. This likely reflects the heterogeneity of an effective COVID-19 immune response. Whether the differences in immune cell dynamics in PLWH will lead to different long-term consequences or compromise vaccination is yet to be determined.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Bill and Melinda Gates Investment INV-018944 to Alex Sigal. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the University of KwaZulu-Natal Institutional Review Board (approval BREC/00001275/2020). Written informed consent was obtained for all enrolled participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll de-identified data is included or available upon request.